Drugs / Enicepatide
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07626515 | Jul 2026 → Apr 2027 expected | — | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT07589686 | Sep 2026 → Nov 2027 expected | obesity disorder | Hoffmann-La Roche | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06628362 | Nov 2024 → May 2026 overdue | obesity disorder, type 2 diabetes mellitus | Carmot Therapeutics, Inc. | Active not recruiting | Met primary |
| Phase 2 | NCT06525935 | Aug 2024 → Dec 2025 | obesity disorder | Carmot Therapeutics, Inc. | Completed | Met primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT07670416 | Jul 2026 → Feb 2028 expected | obesity disorder, type 2 diabetes mellitus | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT07351058 | Mar 2026 → Aug 2028 expected | obesity disorder, type 2 diabetes mellitus | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT07351045 | Mar 2026 → Jul 2028 expected | obesity disorder | Hoffmann-La Roche | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Hoffmann-La Roche | Results Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions roche.com ↗
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity |
| 2026-05-31 | Genentech, Inc. | Results Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions gene.com ↗
Late-breaking data from the Phase II (CT388-103) study will highlight clinical weight loss outcomes from investigational enicepatide in people living with overweight/obesity. |
| 2026-01-27 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity roche.com ↗
The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a weight loss plateau at 48 weeks. |
| 2026-01-26 | Genentech, Inc. | Results Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity gene.com ↗ |
| 2024-05-16 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity roche.com ↗
Basel, 16 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase I clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. |
| 2024-05-15 | Genentech, Inc. | Results Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity gene.com ↗ |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enicepatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06525935 ↗ |
| Action | Activate | “dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA)” NCT07351045 ↗ |
| Route | Subcutaneous | “Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.” NCT06525935 ↗ |